Advertisement
Screener

OPKO Health, Inc. (OPK) Share-based Payment Arrangement, Expense

2.8 / 5 stars · 68/120 Roast Me

OPKO Health, Inc. Share-based Payment Arrangement, Expense

OPKO Health, Inc. (OPK) reported Share-based Payment Arrangement, Expense of $10.70 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-02-26

  • OPKO Health, Inc. share-based payment arrangement, expense for the quarter ending 2022-12-31 was $3.20M, a 13.51% decline year-over-year.
  • OPKO Health, Inc. share-based payment arrangement, expense for the quarter ending 2022-09-30 was $3.40M, a 10.53% decline year-over-year.
  • OPKO Health, Inc. share-based payment arrangement, expense for the quarter ending 2022-06-30 was $4.30M, a 22.86% increase year-over-year.
  • OPKO Health, Inc. share-based payment arrangement, expense for the quarter ending 2022-03-31 was $7.60M, a 192.31% increase year-over-year.
  • OPKO Health, Inc. share-based payment arrangement, expense for fiscal 2025 was $10.70M, a 2.73% decline from fiscal 2024.
  • OPKO Health, Inc. share-based payment arrangement, expense for fiscal 2024 was $11.00M, a 3.51% decline from fiscal 2023.
  • OPKO Health, Inc. share-based payment arrangement, expense for fiscal 2023 was $11.40M, a 38.38% decline from fiscal 2022.
  • OPKO Health, Inc. share-based payment arrangement, expense for fiscal 2022 was $18.50M, a 36.03% increase from fiscal 2021.
Period endShare-based Payment Arrangement, Expense 3 monthShare-based Payment Arrangement, Expense 6 monthShare-based Payment Arrangement, Expense 9 monthShare-based Payment Arrangement, Expense 12 month
2025-12-31$10.70M
10-K · filed 2026-02-26
2024-12-31$11.00M
10-K · filed 2026-02-26
2023-12-31$11.40M
10-K · filed 2026-02-26
2022-12-31$3.20M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03
$6.60M
derived: sum of 2 quarters · filed 2025-03-03
$10.90M
derived: sum of 3 quarters · filed 2025-03-03
$18.50M
10-K · filed 2025-03-03
2022-09-30$3.40M
10-Q · filed 2022-11-08
$7.70M
derived: sum of 2 quarters · filed 2022-11-08
$15.30M
10-Q · filed 2022-11-08
$19.00M
derived: sum of 4 quarters · filed 2024-03-01
2022-06-30$4.30M
10-Q · filed 2022-08-04
$11.90M
10-Q · filed 2022-08-04
$15.60M
derived: sum of 3 quarters · filed 2024-03-01
$19.40M
derived: sum of 4 quarters · filed 2024-03-01
2022-03-31$7.60M
10-Q · filed 2022-05-09
$11.30M
derived: sum of 2 quarters · filed 2024-03-01
$15.10M
derived: sum of 3 quarters · filed 2024-03-01
$18.60M
derived: sum of 4 quarters · filed 2024-03-01
2021-12-31$3.70M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01
$7.50M
derived: sum of 2 quarters · filed 2024-03-01
$11.00M
derived: sum of 3 quarters · filed 2024-03-01
$13.60M
10-K · filed 2024-03-01
2021-09-30$3.80M
10-Q · filed 2022-11-08
$7.30M
derived: sum of 2 quarters · filed 2022-11-08
$9.90M
10-Q · filed 2022-11-08
2021-06-30$3.50M
10-Q · filed 2022-08-04
$6.10M
10-Q · filed 2022-08-04
2021-03-31$2.60M
10-Q · filed 2022-05-09
2020-09-30$2.70M
10-Q · filed 2021-10-28
$4.30M
derived: sum of 2 quarters · filed 2021-10-28
$6.80M
10-Q · filed 2021-10-28
2020-06-30$1.60M
10-Q · filed 2021-07-29
$4.00M
10-Q · filed 2021-07-29
2020-03-31$2.50M
10-Q · filed 2021-04-28
2019-09-30$3.40M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29
$6.50M
derived: sum of 2 quarters · filed 2020-10-29
$11.00M
10-Q · filed 2020-10-29
2019-06-30$3.10M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-31
$7.60M
10-Q · filed 2020-07-31
2019-03-31$4.50M
10-Q · filed 2020-05-06
2018-09-30$5.10M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05
$10.70M
derived: sum of 2 quarters · filed 2019-11-05
$16.60M
10-Q · filed 2019-11-05
2018-06-30$5.60M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07
$11.50M
10-Q · filed 2019-08-07
2018-03-31$5.90M
10-Q · filed 2019-05-08
2017-09-30$6.50M
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09
$12.60M
derived: sum of 2 quarters · filed 2018-11-09
$22.30M
10-Q · filed 2018-11-09
2017-06-30$6.10M
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07
$15.80M
10-Q · filed 2018-08-07
2017-03-31$9.70M
10-Q · filed 2018-05-08
2016-09-30$34.90M
10-Q · filed 2017-11-08
2013-06-30$1.80M
10-Q · filed 2013-08-09
$7.00M
10-Q · filed 2013-08-09
$8.80M
derived: sum of 3 quarters · filed 2013-08-09
$9.90M
derived: sum of 4 quarters · filed 2013-08-09
2013-03-31$5.20M
10-Q · filed 2013-05-10
$7.00M
derived: sum of 2 quarters · filed 2013-05-10
$8.10M
derived: sum of 3 quarters · filed 2013-05-10
$9.10M
derived: sum of 4 quarters · filed 2013-08-09
2012-12-31$1.80M
derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-18
$2.90M
derived: sum of 2 quarters · filed 2013-03-18
$3.90M
derived: sum of 3 quarters · filed 2013-08-09
$5.10M
10-K · filed 2013-03-18
2012-09-30$1.10M
10-Q · filed 2012-11-09
$2.10M
derived: sum of 2 quarters · filed 2013-08-09
$3.30M
10-Q · filed 2012-11-09
$4.90M
derived: sum of 4 quarters · filed 2013-08-09
2012-06-30$1.00M
10-Q · filed 2013-08-09
$2.20M
10-Q · filed 2013-08-09
$3.80M
derived: sum of 3 quarters · filed 2013-08-09
$5.60M
derived: sum of 4 quarters · filed 2013-08-09
2012-03-31$1.20M
10-Q · filed 2013-05-10
$2.80M
derived: sum of 2 quarters · filed 2013-05-10
$4.60M
derived: sum of 3 quarters · filed 2013-05-10
$6.50M
derived: sum of 4 quarters · filed 2013-05-10
2011-12-31$1.60M
derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-18
$3.40M
derived: sum of 2 quarters · filed 2013-03-18
$5.30M
derived: sum of 3 quarters · filed 2013-03-18
$7.00M
10-K · filed 2013-03-18
2011-09-30$1.80M
10-Q · filed 2012-11-09
$3.70M
derived: sum of 2 quarters · filed 2012-11-09
$5.40M
10-Q · filed 2012-11-09
2011-06-30$1.90M
10-Q · filed 2012-08-09
$3.60M
10-Q · filed 2012-08-09
2010-12-31$6.50M
10-K · filed 2013-03-18

Similar stocks

Stock NameCountryMarket CapPE Ratio
LB PHARMACEUTICALS INC (LBRX)United States$1.220B-10.87
HARROW, INC. (HROW)United States$1.240B-42.77
Damora Therapeutics, Inc. (DMRA)$1.250B-6.10
Jaguar Health, Inc. (JAGX)United States$1.184B
Latigo Biotherapeutics, Inc. (LTGO)United States$1.176B
Avalyn Pharma Inc. (AVLN)United States$1.267B
First Tracks Biotherapeutics, Inc. (TRAX)United States$1.280B
Bicara Therapeutics Inc. (BCAX)United States$1.309B-10.55
Seaport Therapeutics, Inc. (SPTX)United States$1.131B
Amphastar Pharmaceuticals, Inc. (AMPH)United States$1.116B10.93